Showing 1 - 20 results of 28 for search '(( significantly ((larger decrease) OR (we decrease)) ) OR ( significant clinical decrease ))~', query time: 0.56s Refine Results
  1. 1

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
  2. 2

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
  3. 3

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
  4. 4

    Data Sheet 1_Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic.docx by Dina Kamel (22434430)

    Published 2025
    “…Overall symptom burden decreased significantly over time (p < 0.001). Vaccination status at baseline was not associated with difference in symptom duration on initial presentation (p = 0.4). …”
  5. 5

    DataSheet1_Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.docx by Cuilin Que (19743256)

    Published 2024
    “…NSTC could improve neurological function in different period of IS, and it has certain clinical value in secondary prevention. As a result of the poor quality and heterogeneity of the included trials, larger and standardized RCTs are needed to validate NSTC in IS treatment.…”
  6. 6
  7. 7
  8. 8
  9. 9

    Supplementary file 2_Effects of Lactiplantibacillus plantarum DSM 33464 in children with elevated blood lead levels: a randomized, double-blind, placebo-controlled study.docx by Wenjing Ji (720509)

    Published 2025
    “…Probiotics have shown promising beneficial effects pre-clinically. Here, we investigated the safety and efficacy of the probiotic Lactiplantibacillus plantarum DSM 33464 in children with elevated blood lead levels.…”
  10. 10

    Supplementary file 1_Effects of Lactiplantibacillus plantarum DSM 33464 in children with elevated blood lead levels: a randomized, double-blind, placebo-controlled study.docx by Wenjing Ji (720509)

    Published 2025
    “…Probiotics have shown promising beneficial effects pre-clinically. Here, we investigated the safety and efficacy of the probiotic Lactiplantibacillus plantarum DSM 33464 in children with elevated blood lead levels.…”
  11. 11
  12. 12
  13. 13
  14. 14

    Table_1_Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.DOC by Na Du (294594)

    Published 2024
    “…DLQI scores decreased from (12.55 ± 4.56) to (2.03 ± 1.13), also showing a statistically significant difference (p < 0.05). …”
  15. 15
  16. 16
  17. 17

    Study group background characteristics. by Zicheng Hu (3825313)

    Published 2024
    “…Other intergroup comparisons were not significant. Overall, the albumin ratio elevations were small, and likely to have had only limited, if any, impact on the CSF proteins measured in this panel. …”
  18. 18
  19. 19

    Supplementary file 1_Brain plasticity underlying acquisition of new organizational skills in children: A Rashomon analysis.docx by Luis Martinez Agulleiro (22810271)

    Published 2025
    “…Future studies should also include alternative control conditions and larger samples.</p>Clinical trial registration<p>https://clinicaltrials.gov/study/NCT04108273?…”
  20. 20

    Image 1_Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report.tif by Tyler Ruemmele (20972594)

    Published 2025
    “…<p>Chimeric Antigen Receptor T (CAR-T) cell therapy significantly and rapidly changed the treatment paradigm for lymphoma, myeloma and leukemia, and the recent approvals of the first cellular immunotherapies in melanoma and synovial sarcoma demonstrate the potential success of this approach in solid tumors. …”